
CHA Vaccine Institute confirms shingles vaccine safety at higher doses
CHA Vaccine Institute, an affiliate of Cha Biotech, announced Tuesday that it has received the clinical study report (CSR) of the Korean phase 1 clinical trial of its recombinant shingles vaccine candidate, CVI VZV 001. According to the report, the safety …